IPILIMUMAB

Ipilimumab is a CTLA4 blocking antibody that enhances immune activation in cancer therapy. Side effects include colitis, dermatitis, hepatitis, and endocrine dysfunction. Only GMP materials will be supplied, logistics all according to GDP.

SKU: bed6c660b720 Category: Tag:

Product Description


Mechanism of Action

IPILIMUMAB exhibits complex multipathway biochemical interactions involving receptorlevel modulation, regulatory enzyme interference, intracellular signalling adjustment and transcriptomic pathway influence. Its physicochemical profile suggests affinity for catalytic and regulatory protein domains, enabling disruption or enhancement of phosphorylation cycles, redoxstate balance, and mitochondrial performance. In several experimental systems, the compound demonstrates capacity to alter calcium signalling, membrane potential, structuralprotein dynamics and cellular metabolic flux.

Benefits and Advantages

This compound supports highresolution biochemical modelling and is suitable for use in:

  • Receptorligand binding studies and pathway validation
  • Metabolicflux assays, mitochondrialstress evaluations and ROSregulation research
  • Multiomics profiling (transcriptomics, metabolomics, proteomics)
  • Stressresponse signalling, kinase/phosphatase cascade mapping and cytoskeletal dynamics analysis
  • Earlyphase pharmacodynamic screening and SAR exploration

Side Effects and Risks

Potential risks include redox imbalance, mitochondrial overload, cytoskeletal disruption, altered membrane integrity, aberrant calcium flux, and dosedependent cytotoxicity. At elevated concentrations, the compound may induce apoptosis, autophagy, or transcriptional stress responses. Use only under strict laboratory conditions with appropriate biosafety protocols and controlled exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

Protein

Molecular Weight

148000.0 g/mol

CAS Number

477202-00-9

Storage Condition

Store at 2-8°C

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

Synonym

477202-00-9; Acid-leached bentonite; Ipilimumab (anti-CTLA-4); SY028004

IUPAC/Chemical Name

Human IgG1 anti-CTLA4 antibody

InChl Key

Unavailable

InChl Code

Unavailable

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download